IRIS
PALLADINI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.148
AS - Asia 6.171
EU - Europa 5.085
SA - Sud America 748
AF - Africa 101
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 20.271
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.960
CN - Cina 3.063
SG - Singapore 1.549
IE - Irlanda 1.475
HK - Hong Kong 844
RU - Federazione Russa 678
BR - Brasile 633
FI - Finlandia 615
DE - Germania 581
UA - Ucraina 469
IT - Italia 361
SE - Svezia 257
GB - Regno Unito 241
VN - Vietnam 232
IN - India 110
CA - Canada 106
FR - Francia 83
PL - Polonia 59
JP - Giappone 58
MX - Messico 57
BD - Bangladesh 50
ZA - Sudafrica 50
ES - Italia 48
AR - Argentina 47
AT - Austria 39
NL - Olanda 34
TR - Turchia 34
BE - Belgio 33
IQ - Iraq 27
PK - Pakistan 25
LT - Lituania 21
CZ - Repubblica Ceca 19
ID - Indonesia 18
IR - Iran 18
EC - Ecuador 14
AE - Emirati Arabi Uniti 13
SA - Arabia Saudita 13
GR - Grecia 12
MA - Marocco 12
AU - Australia 11
CL - Cile 11
TH - Thailandia 11
VE - Venezuela 11
PH - Filippine 10
BG - Bulgaria 9
KZ - Kazakistan 9
LB - Libano 9
MU - Mauritius 9
PY - Paraguay 9
UZ - Uzbekistan 9
KR - Corea 8
RO - Romania 8
AZ - Azerbaigian 7
CO - Colombia 7
EG - Egitto 7
IL - Israele 7
MY - Malesia 7
UY - Uruguay 7
AL - Albania 6
CH - Svizzera 6
JO - Giordania 6
KG - Kirghizistan 6
PE - Perù 6
EU - Europa 5
JM - Giamaica 5
BN - Brunei Darussalam 4
CU - Cuba 4
DK - Danimarca 4
DZ - Algeria 4
IS - Islanda 4
KH - Cambogia 4
PT - Portogallo 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
BO - Bolivia 3
CI - Costa d'Avorio 3
LV - Lettonia 3
MK - Macedonia 3
NG - Nigeria 3
BB - Barbados 2
BH - Bahrain 2
BS - Bahamas 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
ML - Mali 2
NI - Nicaragua 2
PS - Palestinian Territory 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AQ - Antartide 1
CG - Congo 1
CR - Costa Rica 1
DM - Dominica 1
GA - Gabon 1
Totale 20.249
Salva come PNG Salva come JPEG
Città #
Dublin 1.474
Chandler 1.325
Hong Kong 831
Dallas 814
Singapore 732
Ashburn 665
Jacksonville 661
Beijing 626
Nanjing 569
Boardman 357
Helsinki 261
Princeton 259
Lawrence 251
Nanchang 250
Medford 238
Los Angeles 213
Wilmington 209
Shenyang 181
Changsha 162
Hebei 162
Ann Arbor 143
New York 134
Jiaxing 132
Munich 132
Buffalo 121
Redondo Beach 121
Tianjin 117
Shanghai 103
Moscow 100
Hangzhou 97
Ho Chi Minh City 94
Pavia 91
Milan 67
São Paulo 64
Woodbridge 64
Piscataway 63
Hanoi 54
Tokyo 53
Norwalk 51
Warsaw 49
Turku 45
Denver 43
Seattle 43
Falkenstein 38
Montreal 38
The Dalles 38
Johannesburg 35
London 35
Nuremberg 35
Santa Clara 35
Toronto 35
Brussels 32
Chicago 32
Houston 32
Chennai 31
Guangzhou 31
Stockholm 31
Brooklyn 30
Fairfield 30
Pune 28
San Francisco 28
Atlanta 27
Poplar 27
Orem 24
Zhengzhou 24
Ningbo 23
Frankfurt am Main 22
Verona 22
Boston 21
Mexico City 21
Phoenix 20
Brasília 19
Rio de Janeiro 19
Des Moines 18
Charlotte 17
Columbus 16
Kunming 16
Vienna 16
Washington 16
Amsterdam 15
Ankara 15
Manchester 15
Dhaka 14
Jinan 13
Querétaro 13
Belo Horizonte 12
Haiphong 12
Induno Olona 12
Redwood City 11
Taizhou 11
Auburn Hills 10
Baghdad 10
Bangkok 10
Bari 10
Brno 10
Curitiba 10
Hyderabad 10
Athens 9
Düsseldorf 9
Secaucus 9
Totale 13.423
Salva come PNG Salva come JPEG
Nome #
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 132
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 130
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 128
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 126
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 125
Chronic intestinal pseudo-obstruction secondary to al amyloidosis associated with severe gastroparesis: case report 125
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy 125
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 121
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 120
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 113
Amyloid typing: immunoelectron microscopy 113
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 113
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 111
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 110
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 110
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 109
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 109
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 109
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 109
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 108
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 108
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 107
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 107
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 107
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 106
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 106
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 106
Bone marrow amyloidosis. 105
A patient with AL amyloidosis with negative free light chain results 105
Hereditary amyloidosis 103
AMICA: an electronic patient record specifically designed for an amyloidosis network 103
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 103
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 102
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 101
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 100
Clotting alterations in primary systemic amyloidosis. 99
Biochemical markers in early diagnosis and management of systemic amyloidoses 98
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 98
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 98
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 98
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 98
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 98
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 97
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 96
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 96
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 96
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 95
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 95
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 95
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 94
Holter monitoring in AL amyloidosis: prognostic implications. 94
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 94
A practical approach to the diagnosis of systemic amyloidoses 94
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 93
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 92
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 92
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin in primary amyloidosis (AL) 92
Valore prognostico della presenza di disturbi della conduzione cardiaca nei pazienti affetti da amiloidosi AL 92
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 92
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 92
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 92
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 91
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 91
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 91
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 91
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 91
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 90
AMICA: an electronic patient record specifically designed for an amyloidosis network. 90
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 90
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 90
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 90
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 89
Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? 88
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis 88
Clinical aspects of systemic amyloid diseases. 87
Light chain amyloidosis 2012: a new era. 87
Prognostication of survival and progression to dialysis in AA amyloidosis 87
A workflow management system for the biological samples exchange within the amyloidosis network 87
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 86
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 85
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 85
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 85
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 85
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis 84
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 84
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 83
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 83
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 83
Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. 82
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 80
Comment on: parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's Syndrome. 80
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types 80
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 79
The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation 79
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 79
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 79
Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis 79
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 79
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 79
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 78
Totale 9.699
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.654
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.654
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021727 0 0 0 0 0 131 16 192 85 147 126 30
2021/20221.102 21 10 26 11 32 19 11 91 61 42 155 623
2022/20233.826 436 278 47 286 351 350 24 211 1.690 20 85 48
2023/20241.412 181 304 48 109 126 295 33 86 12 43 100 75
2024/20254.073 85 295 96 111 70 283 201 254 990 181 479 1.028
2025/20265.588 774 723 1.049 1.208 1.432 402 0 0 0 0 0 0
Totale 20.768